Investing.com - Can Fite Biopharma ADR reported on Thursday fourth quarter earnings that missed analysts' forecasts and revenue that was inline with expectations.
Can Fite Biopharma ADR announced earnings per share of $-0.135 on revenue of $500K. Analysts polled by Investing.com anticipated EPS of $-0.13 on revenue of $500K.
Can Fite Biopharma ADR shares are up 29.78% from the beginning of the year and are trading at $2.310 , down-from-52-week-high.They are outperforming the EUR/USD which is down 0% from the start of the year.
Can Fite Biopharma ADR shares gained 0.43% in intra-day trade the report.
Can Fite Biopharma ADR follows other major sector earnings this month
Can Fite Biopharma ADR's report follows an earnings missed by Tencent ADR on Wednesday, who reported EPS of $0.3446 on revenue of $20.49B, compared to forecasts EPS of $0.5198 on revenue of $20.33B.
Iberdrola SA had matched expectations on February 24 with fourth quarter EPS of $1.58 on revenue of $10.88B, compared to forecast for EPS of $1.58 on revenue of $12.08B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar